In this dynamic late-breaking science preview Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most anticipated trials of the AHA Scientific Sessions.
What late-breaking trials should we look out for? Which results are likely to impact your practice? What are the considerations and challenges?
Trials covered in detail include:
37s: ISCHEMIA-EXTENDed: Follow-Up Interim Report
2m 59s: ECMO-CS: Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial
5m 37s: TRANSFORM-HF: Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
6m 34s: IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction
8m 46s: RESPECT-EPA: Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
10m 18s: PRECISION: Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease
11m 40s: BRIGHT-4: Bivalirudin With a Post-PCI High-Dose Infusion versus Heparin Monotherapy During Primary PCI in STEMI
12m 47s: SPYRAL HTN-ON: Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results from the SPYRAL HTN-ON Med Expansion Randomized Trial